LONDON, UK / ACCESSWIRE / May 28, 2021 / Oxford Biomedica (OXB) is one of few global lentiviral vector manufacturers with capacity in a thriving cell and gene therapy industry, and its FY20 results highlight strong operational progress throughout the business. OXB boasts a diversified revenue base; and FY20 benefited from new deals including Juno/BMS covering multiple CAR-T programmes, as well as increased bioprocessing and commercial development activities for several customers including Novartis and the AZN COVID-19 vaccine. Post period, OXB upgraded its financial guidance for the COVID-19 vaccine supply agreement with AZN to in excess of £100m by end FY21. In the long term, much value resides in OXB's ability to develop and monetise its own CGT assets, which are progressing towards the clinic. Bolt on acquisitions that complement the pipeline or enhance technology capabilities represent further opportunities. We value OXB at £846m or 1,027p/share.
We increase our valuation of OXB to £846m or 1,027p/share, vs £711m or 892p/share previously. The main source of uplift is the increased expectations of revenue generated from the AZN agreement, which we include for 2021-23. We remove the Sanofi/Bioverativ partnership, delay AXO-Lenti-PD launch by two years to 2026 and update our assumptions for the terminal value. Our valuation does not capture the group's ability to deliver on new customers and expand existing partnerships. Our model reflects net cash of £65.9m (31 March 2021).
Click here to view the full report or here to sign up to receive research as it is published.
All reports published by Edison are available to download free of charge from its website
About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.
Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information, please contact Edison:
Dr Susie Jana +44 (0)20 3077 5700 healthcare@edisongroup.com
Dr John Priestner +44 (0)20 3077 5700 healthcare@edisongroup.com
Learn more at www.edisongroup.com and connect with Edison on:
LinkedIn www.linkedin.com/company/edison-group-/
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv
SOURCE: Edison Investment Research Limited
View source version on accesswire.com:
https://www.accesswire.com/649441/Oxford-Biomedica-OXB-Driving-Innovation-in-a-Thriving-CGT-Industry
